Daily - Oct 16, 2026 - Show Notes
Get personalized biotech intelligence and catalyst tracking from SOZO Intuition:
https://sozointuition.com
CHAPTERS
00:00 Today's Biotech Brief Lead Stories
00:42 FDA Approves Roche's Enspryng for Thyroid Eye Disease
01:17 Enspryng Clinical Profile and SatraGO-2 Efficacy
02:03 Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
02:39 Revita Significantly Reduces Post-GLP-1 Weight Regain
03:26 Mankind Pharma Acquires Majority in Armed Cell
03:56 Armed Cell Platform and Strategic Leadership
04:39 Regulatory Moves: Zilbrysq Autoinjector and Talvey
05:49 Financings and M&A: City Therapeutics and Samsung
06:48 Looking ahead
07:36 SOZO Intuition Platform
SUMMARY
CHAPTERS AND SOURCES
00:00 - Today's Biotech Brief Lead Stories
00:42 - FDA Approves Roche's Enspryng for Thyroid Eye Disease
FDA approves Roche's Enspryng satralizumab, a first-in-class IL-6R inhibitor, as the first at-home subcutaneous treatment for thyroid eye disease 2026-10-16:
https://www.roche.com/media/releases/med-cor-2026-10-16
01:17 - Enspryng Clinical Profile and SatraGO-2 Efficacy
02:03 - Fractyl Reports Pivotal REMAIN-1 Cohort Topline Data
Fractyl Health reports that Revita met the six-month co-primary endpoint in the pivotal REMAIN-1 study, cutting weight regain after GLP-1 discontinuation…:
https://www.globenewswire.com/news-release/2026/10/16/3382499/0/en/fractyl-health-s-revita-meets-six-month-co-primary-endpoint-in-ongoing-remain-1-pivotal-study-with-highly-statistically-significant-reduction-in-weight-regain-after-glp-1-discontin.html
Opus Genetics presents positive clinical data from the OPGx-BEST1 and OPGx-LCA5 gene therapy programs at Retina in Rio 2026 2026-10-16:
https://ir.opusgtx.com/press-releases/detail/545/opus-genetics-presents-positive-clinical-data-from-opgx-best1-and-opgx-
02:39 - Revita Significantly Reduces Post-GLP-1 Weight Regain
03:26 - Mankind Pharma Acquires Majority in Armed Cell
Mankind Pharma enters CAR-T with a EUR 48 million deal for a 70% stake in Belgium's Armed Cell Therapeutics 2026-10-16:
https://www.mankindpharma.com/media/press-release/mankind-pharma-to-acquire-majority-stake-in-armed-cell-therapeutics-marking-strategic-entry-into-next-generation-car-t-therapies/
03:56 - Armed Cell Platform and Strategic Leadership
Acepodia receives TFDA IND approval for ACE723, expanding clinical development to the United States, China and Taiwan 2026-10-16:
https://www.acepodia.com/newsroom-detail/ACE723_IND_TW/
04:39 - Regulatory Moves: Zilbrysq Autoinjector and Talvey
UCB receives U.S. FDA approval for ZILBRYSQ zilucoplan autoinjector self-administration in generalised myasthenia gravis 2026-10-16:
https://www.ucb.com/newsroom/press-releases/article/ucb-announces-us-fda-approval-for-zilbrysqr-zilucoplan-autoinjector-self-administration-for-adults-living-with-generalized-myasthenia-gravis
CHMP recommends approval of Johnson & Johnson's TALVEY talquetamab plus daratumumab in earlier-line relapsed or refractory multiple myeloma 2026-10-16:
https://www.jnj.com/media-center/press-releases/chmp-recommends-approval-of-johnson-johnsons-talvey-talquetamab-plus-daratumumab-in-earlier-line-treatment-of-relapsed-refractory-multiple-myeloma
05:49 - Financings and M&A: City Therapeutics and Samsung
Samsung Biologics publishes the definitive interim result of its tender offer for PolyPeptide with an 87.92% participation rate 2026-10-16:
https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-definitive-interim-result-for-polypeptide-tender-offer
City Therapeutics raises $200 million in an upsized initial public offering, the largest biotech IPO pricing of the week 2026-10-16:
https://www.globenewswire.com/news-release/2026/10/16/3382239/0/en/city-therapeutics-announces-pricing-of-upsized-initial-public-offering.html
Soufflé Therapeutics raises an oversubscribed $135 million Series B to advance its RNA delivery platform 2026-10-16:
https://www.citybiz.co/article/919851/souffle-therapeutics-raises-135m-to-advance-rna-delivery-platform/
06:48 - Looking ahead
Shareholders of Indivior and Supernus Pharmaceuticals approve their all-stock merger of equals 2026-10-16:
https://www.indivior.com/latest/category/company-statements/2026/indivior-shareholders-approve-proposed-merger-with-supernus
Edesa Biotech receives FDA IND clearance for a Phase 2 study of EB06 in vitiligo 2026-10-16:
https://www.biospace.com/press-releases/edesa-biotech-announces-fda-ind-clearance-for-phase-2-vitiligo-study
Eclipse Life Sciences reports positive Phase 2 BETTIS-1 topline results for EC-104 in diabetic macular edema 2026-10-16:
https://www.globenewswire.com/news-release/2026/10/15/3381495/0/en/eclipse-life-sciences-announces-positive-topline-results-from-phase-2-bettis-1-study-evaluating-ec-104-for-diabetic-macular-edema-dme.html
Additional references omitted to fit YouTube's 5,000-character limit.